The following diseases are designated as SEC Cancers:

(1)  Primary or secondary* lung cancer, including sarcoma of the lung (excludes in situ lung cancer discovered during or after a post-mortem exam, mesothelioma or pleura cancer);

(2)  Primary or secondary* bone cancer (including associated blood disorders – see below** and solitary plasmacytomoa);
(3)  Primary or secondary* renal (kidney) cancer.

(4)  Leukemia (excludes CLL) if onset was at least two years after first exposure.

The following diseases, if onset was at least five years after first exposure:
(5)  Multiple myeloma;
(6)  Lymphomas (excludes Hodgkin’s disease; includes Waldenstrom’s   macroglobulinemia).
(7)  Primary cancer of the:

  • (A) thyroid
  • (B) male or female breast
  • (C) esophagus
  • (D) stomach
  • (E) pharynx, including all three areas, oropharynx, nasopharynx and hypopharynx.  The oropharynx includes the soft palate, the base of the tonque and the tonsils.
  • (F) small intestine
  • (G) pancreas
  • (H) bile ducts, including Ampulla of Vater
  • (I) gall bladder
  • (J) salivary gland
  • (K) urinary bladder
  • (L) brain (malignancies only, not including intracranial endocrine glands and other parts of the central nervous system or borderline astrocytomas)
  • (M) colon, including rectum and appendix
  • (N) ovary
  • (O) liver (except if cirrhosis or hepatitis B is indicated)

Other malignant cancers (Prostate, Skin Cancer, etc.) may be compensable.  Prostate Cancer with metastasis (“W/METS”) or multiple occurrences of skin cancer(s) require further evaluation.

* Secondary cancers are typically diagnosed as having been caused by metastasis (spread) from primary cancers.

** Bone cancer blood disorders – Bone form of solitary plasmacytoma, myelodysplastic syndrome, myelofibrosis with myeloid metaplasia, essential thrombocytosis or essential thrombocythemia, primary polycythemia vera [also called polycythemia rubra vera, P. vera, primary polycythemia, proliferative polycythemia, spent-phase polycythemia or primary erythremia].